Locate Bio is an innovative UK MedTech company specializing in orthobiologics, focusing on developing advanced solutions for musculoskeletal needs. One of their key products, LDGraft™, is a pre-encapsulated recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) designed to enhance lumbar interbody fusion procedures. This product aims to eliminate the variability associated with traditional rhBMP-2 applications by controlling and extending the release of the protein over approximately five weeks. LDGraft™ has received FDA Breakthrough Device designation for its use in Anterior Lumbar Interbody Fusion (ALIF) for patients with degenerative disc disease, highlighting its potential to significantly improve surgical outcomes.

In addition to LDGraft™, Locate Bio is also developing CertOss™, a novel synthetic bone graft, and OsteoMime™, another rhBMP-2 product currently in the early stages of development. The company emphasizes a rigorous research and development process to create products that not only meet but exceed current standards in the field. Their commitment to innovation is reflected in their focus on providing surgeons with best-in-class options that can effectively relieve suffering and restore quality of life for patients undergoing orthopedic procedures.

United Kingdom

Locate Bio bring together Programmed Drug Release and Instructive Tissue Scaffolds to develop the next generation of products with significant disruptive potential for musculoskeletal conditions.

Locate Bio

Company Details